KR100897938B1 - 면역글로불린 융합 단백질 - Google Patents

면역글로불린 융합 단백질 Download PDF

Info

Publication number
KR100897938B1
KR100897938B1 KR1020087018012A KR20087018012A KR100897938B1 KR 100897938 B1 KR100897938 B1 KR 100897938B1 KR 1020087018012 A KR1020087018012 A KR 1020087018012A KR 20087018012 A KR20087018012 A KR 20087018012A KR 100897938 B1 KR100897938 B1 KR 100897938B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
ser
delete delete
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087018012A
Other languages
English (en)
Korean (ko)
Other versions
KR20080094781A (ko
Inventor
성영철
양세환
Original Assignee
주식회사 제넥신
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 제넥신, 포항공과대학교 산학협력단 filed Critical 주식회사 제넥신
Publication of KR20080094781A publication Critical patent/KR20080094781A/ko
Application granted granted Critical
Publication of KR100897938B1 publication Critical patent/KR100897938B1/ko
Assigned to 포항공과대학교기술지주 주식회사 reassignment 포항공과대학교기술지주 주식회사 권리지분의 전부이전등록 Assignors: 포항공과대학교 산학협력단
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
KR1020087018012A 2007-05-30 2008-05-30 면역글로불린 융합 단백질 Active KR100897938B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94075307P 2007-05-30 2007-05-30
US60/940,753 2007-05-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097008080A Division KR101380732B1 (ko) 2007-05-30 2008-05-30 면역글로불린 융합 단백질

Publications (2)

Publication Number Publication Date
KR20080094781A KR20080094781A (ko) 2008-10-24
KR100897938B1 true KR100897938B1 (ko) 2009-05-18

Family

ID=40088983

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020087018012A Active KR100897938B1 (ko) 2007-05-30 2008-05-30 면역글로불린 융합 단백질
KR1020097008080A Active KR101380732B1 (ko) 2007-05-30 2008-05-30 면역글로불린 융합 단백질
KR1020147004294A Active KR101380729B1 (ko) 2007-05-30 2008-05-30 면역글로불린 융합 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020097008080A Active KR101380732B1 (ko) 2007-05-30 2008-05-30 면역글로불린 융합 단백질
KR1020147004294A Active KR101380729B1 (ko) 2007-05-30 2008-05-30 면역글로불린 융합 단백질

Country Status (14)

Country Link
US (5) US7867491B2 (https=)
EP (4) EP3173484B1 (https=)
JP (1) JP5577243B2 (https=)
KR (3) KR100897938B1 (https=)
CN (5) CN105131127B (https=)
AU (1) AU2008257923B2 (https=)
BR (1) BRPI0811637B8 (https=)
CA (1) CA2687377C (https=)
DK (1) DK2662449T3 (https=)
ES (2) ES2623925T3 (https=)
HK (1) HK1219490A1 (https=)
IL (1) IL202128A0 (https=)
RU (1) RU2530168C2 (https=)
WO (1) WO2008147143A2 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150110571A (ko) * 2013-02-01 2015-10-02 리제너론 파아마슈티컬스, 인크. 키메라 불변 도메인을 포함하는 항체
KR20170045197A (ko) * 2014-06-26 2017-04-26 칼 에이. 겐버그 진균 감염 치료 방법
KR20170047559A (ko) * 2015-10-23 2017-05-08 주식회사 제넥신 피부 주름 개선용 조성물
KR101773858B1 (ko) 2015-10-23 2017-09-01 명지대학교 산학협력단 피부 주름 개선용 조성물
WO2019209078A1 (ko) 2018-04-26 2019-10-31 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020022782A1 (ko) 2018-07-24 2020-01-30 주식회사 굳티셀 면역 관련 질환의 예방 또는 치료용 조성물
WO2020231199A1 (ko) 2019-05-14 2020-11-19 주식회사 프로젠 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
WO2021006604A1 (ko) 2019-07-08 2021-01-14 주식회사 프로젠 신규 융합단백질 및 그의 용도
WO2021006605A1 (ko) 2019-07-08 2021-01-14 주식회사 프로젠 신규 il-10 변이체 단백질 및 그의 용도
WO2021182928A1 (ko) 2020-03-12 2021-09-16 주식회사 에스엘메타젠 신규 이중 특이성 단백질 및 그의 용도
WO2022131889A1 (ko) 2020-12-16 2022-06-23 주식회사 굳티셀 Taci 단백질의 용도
US11479596B2 (en) 2018-07-25 2022-10-25 Yuhan Corporation Fusion protein comprising thyrotropin receptor variants and use thereof
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
WO2024263005A1 (ko) 2023-06-22 2024-12-26 주식회사 에스엘바이젠 신규 이중 특이성 융합단백질 및 그의 용도

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
KR101030978B1 (ko) * 2008-07-10 2011-04-28 (주) 에이프로젠 동물세포용 재조합 발현벡터
CN101747440B (zh) * 2008-12-18 2014-05-07 嘉和生物药业有限公司 一种TNFR-Fc融合蛋白及其用途
US20110117092A1 (en) * 2009-10-20 2011-05-19 The Regents Of The University Of Michigan Compositions and methods for inhibiting g-csfr
CN102947341B (zh) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 用于病原体检测和治疗的工程化调理素
CN102260343A (zh) * 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
WO2012032520A1 (en) * 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
US20130302343A1 (en) 2011-01-04 2013-11-14 Charité Universitätsmedizin Berlin Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
BR112013021661A2 (pt) 2011-03-02 2016-11-22 Novo Nordisk As objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas
CN110551223A (zh) * 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
WO2013006486A2 (en) * 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CN103732240B (zh) * 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
EP2793943B1 (en) 2011-12-19 2018-09-26 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
KR101183615B1 (ko) * 2011-12-28 2012-09-17 재단법인 경기과학기술진흥원 Ｗｎｔ에 결합하는 신규한 재조합 단백질
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
WO2013138338A2 (en) 2012-03-12 2013-09-19 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apoliporotein d
WO2013162050A1 (ja) * 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
JP6026002B2 (ja) 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US20160017017A1 (en) * 2013-03-11 2016-01-21 Novo Nordisk Healthcare Ag Growth Hormone Compounds
WO2014152955A1 (en) * 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
CN105916881A (zh) 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
AU2015270152A1 (en) 2014-06-02 2016-12-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of Fc fragments
KR102272213B1 (ko) * 2014-07-08 2021-07-01 삼성전자주식회사 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도
US20160108105A1 (en) * 2014-10-06 2016-04-21 Genexine, Inc. Human igg4 fc polypeptide variant
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
CN110204617B (zh) * 2014-12-31 2023-06-16 天境生物科技(上海)有限公司 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
EP3243525A4 (en) * 2015-01-09 2018-07-25 Genexine, Inc. Method for treating anemia using long-acting epo preparation
AU2016226115B2 (en) 2015-03-04 2021-03-25 The Rockefeller University Anti-inflammatory polypeptides
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
CA2979973A1 (en) * 2015-04-29 2016-11-03 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
JP2018515073A (ja) 2015-05-04 2018-06-14 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｆｃ融合タンパク質のトランスジェニック産生
WO2016178087A1 (en) 2015-05-04 2016-11-10 Biosourcing Sa Transgenic production of chorionic gonadotropin
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
US10208099B2 (en) 2015-06-11 2019-02-19 Genexine, Inc. Modified interleukin-7 protein
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
CN108136043B (zh) 2015-10-01 2022-09-06 诺和诺德股份有限公司 蛋白质缀合物
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
WO2017095191A1 (ko) * 2015-12-04 2017-06-08 주식회사 제넥신 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
WO2017095140A1 (ko) * 2015-12-04 2017-06-08 주식회사 제넥신 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
KR20170096968A (ko) 2016-02-17 2017-08-25 주식회사 제넥신 hGH 융합단백질을 포함하는 성장호르몬 결핍을 치료하기 위한 약학 조성물
WO2017142331A1 (en) 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
KR102682118B1 (ko) * 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
CN106191072A (zh) * 2016-08-04 2016-12-07 沈沭彤 重组人源嵌合GcFc基因片段及融合蛋白
US12427186B2 (en) * 2016-08-30 2025-09-30 Genexine, Inc. Method for treating growth hormone deficiency employing hGH fusion protein
WO2018053234A1 (en) 2016-09-15 2018-03-22 Acceleron Pharma, Inc. Twisted gastrulation polypeptides and uses thereof
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
CA3080406A1 (en) 2016-10-28 2018-05-03 Nrl Pharma, Inc. Lactoferrin/albumin fusion protein and production method thereof
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3538560B1 (en) * 2016-11-10 2026-04-08 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
CN108264562B (zh) * 2016-12-30 2021-08-10 惠和生物技术(上海)有限公司 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
CN106832002A (zh) * 2017-02-16 2017-06-13 上海科医联创生物科技有限公司 一种靶向pd‑1的融合蛋白及其相关应用
CN117986384A (zh) 2017-03-06 2024-05-07 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
CN108623692B (zh) * 2017-03-20 2020-11-17 徐寒梅 一种融合蛋白及其制备方法和其应用
CN110505885A (zh) 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
IL270596B2 (en) 2017-05-25 2026-01-01 Bristol Myers Squibb Co Antibodies containing heavy constant regions are adapted for use in cancer therapy
CN107082815A (zh) * 2017-06-28 2017-08-22 杭州皓阳生物技术有限公司 一种fsh‑hsa融合蛋白及其制备方法
CN111566214B (zh) * 2017-07-06 2024-03-08 日东纺绩株式会社 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂
US11883503B2 (en) 2017-09-25 2024-01-30 Dingfu Biotarget Co., Ltd. Methods and compositions for cancer treatment
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
MX2020006635A (es) * 2017-12-22 2020-12-10 Hanmi Pharm Ind Co Ltd Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
KR102038672B1 (ko) * 2018-01-08 2019-10-30 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물
AU2019205743B2 (en) * 2018-01-08 2023-11-16 Gi Innovation, Inc. Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same
EP3738599B1 (en) 2018-01-12 2023-12-27 GI Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
US20190218285A1 (en) * 2018-01-18 2019-07-18 Molecular Cloning Laboratories (MCLAB) LLC Long-Acting Therapeutic Fusion Proteins
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2019212429A2 (en) 2018-05-04 2019-11-07 İlkogen İlaç Sanayi̇ Ve Ti̇caret A.Ş. Stable hybrid fc fusion g-csf formulation
CA3106563A1 (en) 2018-07-26 2020-01-30 Atyr Pharma, Inc. Compositions and methods for treating nrp2-associated diseases
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
EP3848388B1 (en) * 2018-09-05 2025-08-20 LG Chem, Ltd. Fusion polypeptide comprising polypeptide region that can be o-glycosylated
WO2020053661A1 (en) 2018-09-13 2020-03-19 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan
EP3880231A1 (en) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
AU2020220651B2 (en) 2019-02-13 2026-01-15 Ilkogen Ilac Sanayi Ve Ticaret A.S. A long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
WO2020184941A1 (en) * 2019-03-08 2020-09-17 Genexine, Inc. Glp-1 fusion proteins and uses thereof
EP3744319B1 (en) * 2019-05-28 2022-10-19 Ilkogen Ilac Sanayi Ve Ticaret A.S. A stable lyophilized formulation for hybrid fc fused g-csf
KR20210006300A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
BR112022000246A2 (pt) * 2019-07-08 2022-02-22 Gi Innovation Inc Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo
WO2021006375A1 (ko) * 2019-07-08 2021-01-14 (주)지아이이노베이션 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물
BR112022011540A2 (pt) * 2019-12-11 2022-09-06 Lg Chemical Ltd Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero
CN111057154B (zh) * 2019-12-23 2023-06-06 南京融捷康生物科技有限公司 基于驼源Fc片段的免疫原的制备及应用
IL294663A (en) 2020-01-13 2022-09-01 Neoimmunetech Inc Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
CN115103685B (zh) * 2020-01-23 2025-08-05 格纳西尼有限公司 包含程序性细胞死亡配体1蛋白的融合蛋白及其用途
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
CN116096733A (zh) * 2020-04-10 2023-05-09 阿卡斯通生物科学公司 Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
WO2021230705A1 (ko) * 2020-05-14 2021-11-18 주식회사 프로젠 신규 재조합 융합단백질 및 그의 용도
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2022000136A1 (en) * 2020-06-28 2022-01-06 Dingfu Biotarget Co., Ltd. Methods and compositions for cancer treatment
CN111944058B (zh) * 2020-07-28 2021-12-17 中国农业大学 一种兼具抗菌、抗炎、中和内毒素和免疫调节活性的多功能杂合肽及其制备方法和应用
KR102450007B1 (ko) * 2020-10-16 2022-10-04 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
WO2022093718A1 (en) 2020-10-26 2022-05-05 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2022191550A1 (ko) 2021-03-09 2022-09-15 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
WO2023096475A1 (ko) 2021-11-26 2023-06-01 주식회사 제넥신 Hgh 융합단백질의 고농도 투여 제형
KR20240130705A (ko) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
US20250188182A1 (en) 2022-03-10 2025-06-12 Genexine, Inc. Triple combination drug dosing therapy for head and neck cancer treatment
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
CN115850517B (zh) * 2022-11-14 2024-10-11 沈阳药科大学 一种提高GLP-1 Fc融合蛋白产量的方法
EP4682164A1 (en) 2023-03-17 2026-01-21 Curogen Technology Co., Ltd. Novel fusion protein for treating autoimmune diseases
WO2025010272A1 (en) * 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
RU2319709C2 (ru) * 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
KR100956913B1 (ko) * 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102229732B1 (ko) * 2013-02-01 2021-03-22 리제너론 파아마슈티컬스, 인크. 키메라 불변 도메인을 포함하는 항체
KR20150110571A (ko) * 2013-02-01 2015-10-02 리제너론 파아마슈티컬스, 인크. 키메라 불변 도메인을 포함하는 항체
KR20170045197A (ko) * 2014-06-26 2017-04-26 칼 에이. 겐버그 진균 감염 치료 방법
KR102601412B1 (ko) 2014-06-26 2023-11-13 브라이엄 영 유니버시티 진균 감염 치료 방법
KR20170047559A (ko) * 2015-10-23 2017-05-08 주식회사 제넥신 피부 주름 개선용 조성물
KR101773858B1 (ko) 2015-10-23 2017-09-01 명지대학교 산학협력단 피부 주름 개선용 조성물
KR102147997B1 (ko) * 2015-10-23 2020-08-25 주식회사 제넥신 피부 주름 개선용 조성물
WO2019209078A1 (ko) 2018-04-26 2019-10-31 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020022782A1 (ko) 2018-07-24 2020-01-30 주식회사 굳티셀 면역 관련 질환의 예방 또는 치료용 조성물
US11479596B2 (en) 2018-07-25 2022-10-25 Yuhan Corporation Fusion protein comprising thyrotropin receptor variants and use thereof
WO2020231199A1 (ko) 2019-05-14 2020-11-19 주식회사 프로젠 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
KR20210155395A (ko) * 2019-05-14 2021-12-22 주식회사 프로젠 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
KR20220080221A (ko) * 2019-05-14 2022-06-14 주식회사 프로젠 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
KR102408608B1 (ko) 2019-05-14 2022-06-15 주식회사 프로젠 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
KR102700583B1 (ko) 2019-05-14 2024-08-29 주식회사 프로젠 신규 변형 면역글로불린 fc 융합단백질 및 그의 용도
US12545713B2 (en) 2019-05-14 2026-02-10 Progen Co., Ltd. Modified immunoglobulin Fc-fusion protein and use thereof
WO2021006604A1 (ko) 2019-07-08 2021-01-14 주식회사 프로젠 신규 융합단백질 및 그의 용도
WO2021006605A1 (ko) 2019-07-08 2021-01-14 주식회사 프로젠 신규 il-10 변이체 단백질 및 그의 용도
WO2021182928A1 (ko) 2020-03-12 2021-09-16 주식회사 에스엘메타젠 신규 이중 특이성 단백질 및 그의 용도
WO2022131889A1 (ko) 2020-12-16 2022-06-23 주식회사 굳티셀 Taci 단백질의 용도
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof
WO2024263005A1 (ko) 2023-06-22 2024-12-26 주식회사 에스엘바이젠 신규 이중 특이성 융합단백질 및 그의 용도

Also Published As

Publication number Publication date
EP2662449B1 (en) 2017-02-15
EP2662449A3 (en) 2015-11-18
EP3173484B1 (en) 2018-09-26
HK1219284A1 (zh) 2017-03-31
EP3176264A1 (en) 2017-06-07
IL202128A0 (en) 2010-06-16
EP2162472A4 (en) 2012-05-09
CN103641919B (zh) 2017-04-05
RU2530168C2 (ru) 2014-10-10
EP2162472A2 (en) 2010-03-17
BRPI0811637B1 (pt) 2020-11-24
CN103641919A (zh) 2014-03-19
CN101687933B (zh) 2015-11-25
CN101687933A (zh) 2010-03-31
KR20090045953A (ko) 2009-05-08
AU2008257923A1 (en) 2008-12-04
EP3173484A1 (en) 2017-05-31
KR101380729B1 (ko) 2014-04-10
CA2687377C (en) 2013-05-14
US8586048B2 (en) 2013-11-19
JP5577243B2 (ja) 2014-08-20
JP2010531134A (ja) 2010-09-24
HK1141303A1 (zh) 2010-11-05
US20120276097A1 (en) 2012-11-01
BRPI0811637A2 (pt) 2014-11-18
EP2662449A2 (en) 2013-11-13
CN105131127A (zh) 2015-12-09
EP2162472B1 (en) 2013-02-27
US20120276043A1 (en) 2012-11-01
HK1218127A1 (zh) 2017-02-03
US8529899B2 (en) 2013-09-10
CN103626875B (zh) 2016-01-13
BRPI0811637B8 (pt) 2021-05-25
US7867491B2 (en) 2011-01-11
US20110091416A1 (en) 2011-04-21
RU2009141975A (ru) 2011-05-20
KR20080094781A (ko) 2008-10-24
KR101380732B1 (ko) 2014-04-10
WO2008147143A2 (en) 2008-12-04
CN105198998A (zh) 2015-12-30
HK1191959A1 (zh) 2014-08-08
AU2008257923B2 (en) 2013-03-21
CN103626875A (zh) 2014-03-12
CA2687377A1 (en) 2008-12-04
ES2623925T3 (es) 2017-07-12
US8586531B2 (en) 2013-11-19
US20120276096A1 (en) 2012-11-01
HK1219490A1 (zh) 2017-04-07
DK2662449T3 (en) 2017-05-15
WO2008147143A3 (en) 2009-02-26
US8586038B2 (en) 2013-11-19
CN105131127B (zh) 2018-09-07
ES2415604T3 (es) 2013-07-26
US20080300188A1 (en) 2008-12-04
KR20140037961A (ko) 2014-03-27
EP3176264B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
KR100897938B1 (ko) 면역글로불린 융합 단백질
AU2004309050B2 (en) IL-7 fusion proteins
KR20080095141A (ko) 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
CN105175553B (zh) 免疫球蛋白融合蛋白
HK1191959B (en) Immunoglobulin fusion proteins
HK1191347B (en) Immunoglobulin fusion proteins
HK1219284B (zh) 免疫球蛋白融合蛋白
HK1141303B (en) Immunoglobulin fusion proteins
HK1191347A (en) Immunoglobulin fusion proteins
MXPA06007377A (en) Il-7 fusion proteins
HK1218127B (en) Immunoglobulin fusion proteins

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
PA0105 International application

Patent event date: 20080722

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PA0302 Request for accelerated examination

Patent event date: 20080722

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081224

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090326

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090420

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20090507

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090508

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090511

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20120323

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130314

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130314

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140421

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140421

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150227

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160229

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160229

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170303

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170303

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180305

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180305

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210504

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20220504

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20230417

Start annual number: 15

End annual number: 15